Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study-Reference-Cited by-同舟云学术

Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study

Published:2022-10 Issue: Volume:65 Page:136-144
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Vasseur Antoine,Carton Matthieu,Guiu Severine,Augereau Paule,Uwer Lionel,Mouret-Reynier Marie-Ange,Levy Christelle,Eymard Jean-Christophe,Ferrero Jean-Marc,Leheurteur Marianne,Goncalves Anthony,Robert Marie,De La Motte Rouge Thibault,Bachelot Thomas,Petit Thierry,Debled Marc,Grinda Thomas,Desmoulins Isabelle,Vanlemmens Laurence,Nicolaï Vincent,Simon Gaëtane,Cabel Luc^ORCID

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference36 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;Ca - Cancer J Clin,2018

2. Residual risk of breast cancer recurrence 5 years after adjuvant therapy;Brewster;J Natl Cancer Inst,2008

3. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis;Dieci;Ann Oncol,2013

4. Weekly paclitaxel in the adjuvant treatment of breast cancer;Sparano;N Engl J Med,2008

5. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer;Tolaney;N Engl J Med,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer;Annals of Oncology;2024-07

2. EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer;Cancers;2024-04-12

3. Efficacy of anlotinib in Chinese patients with metastatic breast cancer: A retrospective observational study;Journal of Cellular and Molecular Medicine;2023-10-27

4. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort;European Journal of Cancer;2023-08

5. Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results;The Breast;2023-04